Basic HTML Version
VOLUME 9 NUMBER 1 • MARCH 2012
41
SA JOURNAL OF DIABETES & VASCULAR DISEASE
REPORT
Sponsored by Novo Nordisk
Novo Nordisk (Pty) Ltd. Reg. No.: 1959/000833/07. PO Box 783155, Sandton, 2146. Tel: (011) 202 0500 Fax: (011) 807 7989 NN/DUO/4145/07/10/VER1
trol was retained for a terminal half-life of
25 hours. Insulin degludec was well toler-
ated and there were no safety concerns.
A second study was presented at the
IDF following the earlier published observa-
tion that insulin degludec has less within-
subject variability than insulin glargine in
treating type 1 diabetes patients. This study
evaluated whether this reduced variability
was constant over the 24-hour period at
steady state.
Using euglycaemic glucose clamps on
the sixth, ninth and twelfth days of treat-
ment, area-under-the-curve (AUC) evalu-
ations of glucose infusions over 24 hours
showed less variability with insulin deglu-
dec than with insulin glargine, perhaps due
to the slow release of IDeg monomers from
the soluble multi-hexamers that form after
subcutaneous injection.
10,11
References
Niskanen Initial,
1.
et al
. IDegAsp, a soluble insulin
combination of ultra-long-acting insulin degludec
and insulin aspart, in type 2 diabetes: comparison
with biphasic insulin aspart 30. NN data on file
(1792) IDF abstract P-1437.
Hirsch initial,
2.
et al
. BOOST™ T1 IDegAsp, a soluble
insulin combination of ultra-long-acting insulin
degludec and insulin aspart, used once daily in
basal-bolus treatment with insulin aspart in type
1 diabetes. NN data on file (3594) IDF abstract
P-1438.
Vaag A,
3.
et al
. IDEGASP, a soluble insulin
combination of ultra-long-acting insulin degludec
and insulin aspart, in type 2 diabetes: comparison
with biphasic insulin aspart 30. Poster 1040,
presented at European Association for the Studies
of Diabetes (EASD), Lisbon, September, 2011.
Heise T,
4.
et al
. Insulin degludec: two fold longer
half-life and a more consistent pharmacokinetic
profile compared to insulin glargine. NN data on
file (1993) IDF abstract P-1444.
Kurtzhals P,
5.
et al
. Multi-hexamer formation is
the underlying basis for the ultra-long glucose
lowering effect of insulin degludec. Poster 1049,
presented at European Association for the Studies
of Diabetes (EASD), Lisbon, September, 2011.
Garber A,
6.
et al
. Insulin degludec improves long-
term glycaemic control with a lower rate of hypo-
glycaemia vs. insulin glargine in type 2 diabetes.
NN data on file (3582) IDF abstract P-1442.
Heller S,
7.
et al
. Induced hypoglycaemia in type 1
diabetes: enhanced counter-regulatory hormone
response with insulin Degludec versus insulin
glargine. NN data on file (3538) IDF abstract
D-0723.
Home PD,
8.
et al
. Poster 941, presented at European
Association for the Studies of Diabetes (EASD),
Lisbon, September, 2011.
Atkin SL,
9.
et al
. Oral presentation, abstract 112,
presented at European Association for the Studies
of Diabetes (EASD), Lisbon, September, 2011.
Nosek L,
10.
et al
. Ultra-long-acting degludec has a
flat and stable glucose-lowering affect. Poster
P-1452, IDF congress, 2011.
Heise T,
11.
et al
. Ultra-long-acting insulin degludec
has consistently lowered pharmacodynamic
variability than insulin glargine over 24 h at steady
state. Poster P-1453, IDF congress, 2011.